Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Aldesleukin + GD2Bi-aATC + Sargramostim |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Aldesleukin | Proleukin | IL-2|Interleukin-2|IL2 | Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary). | |
GD2Bi-aATC | anti-CD3 x hu3F8 bispecific antibody-armed ATC | GD2Bi-aATC are autologous T-cells that have been armed with bispecific antibodies that target both GD2 and CD3, resulting in cytotoxicity of GD2-expressing tumor cells by cross-linking activated T-cells to GD2-positive tumor cells, and may also enhance CTL-mediated response tumor cells (NCI Drug Dictionary). | ||
Sargramostim | Leukine | GM-CSF|Prokine |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |